Endoscopic ultrasound in pancreatic cancer treatment: Facts and hopes.
Journal
Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
18
11
2018
revised:
12
02
2019
accepted:
16
02
2019
pubmed:
3
4
2019
medline:
21
10
2020
entrez:
3
4
2019
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma is one of the most common causes of cancer-related deaths. Since most patients present with advanced disease, its prognosis is dismal. New and more effective therapeutic strategies are needed. Endoscopic ultrasound is currently an indispensable tool for the diagnosis and staging of pancreatic ductal adenocarcinoma. In recent years, endoscopic ultrasound has evolved to become also a therapeutic procedure. On one hand, the role of endoscopic ultrasound in the management of pancreatic cancer-related symptoms (pain, obstructive jaundice, and gastric outlet obstruction) is now well established. On the other hand, its use as a mean to the delivery of anti-tumor therapies (injecting anti-tumor agents, assisting in radiotherapy, and guiding ablative therapies) is still mostly experimental, despite growing evidence supporting its feasibility, safety and efficacy.
Identifiants
pubmed: 30935904
pii: S2210-7401(19)30056-7
doi: 10.1016/j.clinre.2019.02.014
pii:
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
513-521Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.